Written questions by Anderson.

What steps he is taking to reduce the time taken to diagnose Parkinson's.

We recognise the importance of a timely diagnosis of Parkinson’s disease and remain committed to delivering the National Health Service constitutional standard for 92% of patients to wait no longer than 18 weeks from Referral to Treatment by March 2029. We are investing in additional capacity to deliver appointments to help bring lists and waiting times down. Our Elective Reform Plan, published in January 2025, sets out the specific productivity and reform efforts needed to return to the constitutional standard.By expanding community-based services for routine monitoring and follow-up, employing artificial intelligence for productivity and investing in digital tools and data, as outlined in the 10-Year Health Plan, we can ensure that consultants’ time is reserved for complex cases, including specialist diagnostic assessments, which are critical for people with suspected Parkinson’s.Integrated care boards (ICBs) are responsible for commissioning services that meet the needs of their population, including for Parkinson’s. In doing so, the Government expects ICBs to take account of the relevant guidelines and best practice in designing their local services. The National Institute for Health and Care Excellence guideline on Parkinson’s disease (NG71) states that people with Parkinson’s should have an accessible point of contact with specialist services, which can be provided by a Parkinson’s nurse specialist, and that all individuals should be offered access to the services provided by these specialist nurses to support ongoing care and advice.The guideline is available at the following link:https://www.nice.org.uk/guidance/ng71We acknowledge the significant neurology workforce challenges across the country, including the need for more specialist nurses. The forthcoming 10 Year Workforce Plan will set out how we will we train and provide the staff, technology, and infrastructure the NHS needs to make it more accessible, proactive, and tailored for all patients, including those with Parkinson’s.

What steps he is taking to reduce wait times to see a neurologist.

Cutting waiting lists is a key priority for the Government. We have exceeded our pledge to deliver an extra two million operations, scans, and appointments, having delivered 5.2 million more appointments across elective care services. This marks a vital first step to delivering on the commitment that 92% of patients will wait no longer than 18 weeks from referral to consultant-led treatment, in line with the National Health Service constitutional standard, by March 2029.Between September 2024 and 2025, we reduced the number of incomplete neurology pathways by over 15,000, from 234,720 to 219,221, and reduced the average waiting time for neurology services from 16.2 to 15.2 weeks. 57.2% of patients referred were waiting within 18 weeks, up from 54% at the same point last year. This is still lower than the national average and we are continuing efforts to improve this, recognising that this is a challenged specialty.The January 2025 Elective Reform Plan commits to reforming outpatient services, including by supporting general practitioners and hospital doctors to work better together to ensure referrals are used only when a patient really needs hospital care, through increased uptake of Advice and Guidance. There are a number of initiatives at the national level supporting service improvement and better care for patients with neurological conditions, including the United Kingdom-wide Neuro Forum, RightCare Progressive Neurological Conditions Toolkit, and the Getting It Right First Time Programme for Neurology.

What steps he is taking to help improve access to affordable home adaptations for people with motor neurone disease.

We recognise how important the right housing arrangements are in supporting people to live as independently and safely as possible. In England, we continue to fund the Disabled Facilities Grant (DFG), which is administered by local authorities. This grant helps eligible older and disabled people on low incomes, including people with motor neurone disease, to adapt their homes.We have provided an additional £172 million over this and the last financial year to uplift the DFG. This uplift could provide approximately 15,600 extra home adaptations to give people more independence in their homes. This brings the total funding for the DFG to £711 million in each of 2024/25 and 2025/26.

What steps he is taking to support social care staff working in supported living accommodation.

The Government recognises the vital role of social care staff working in supported living accommodation in enabling people to live independently with dignity.We are committed to transforming adult social care and supporting adult social care workers, turning the page on decades of low pay and insecurity. That is why we plan to introduce the first ever Fair Pay Agreement in 2028, backed by £500 million of funding to improve pay and conditions for the adult social care workforce. This will improve recruitment and retention and give staff better recognition for their vital work. The £500 million forms part of an increase of over £4 billion of additional funding available for adult social care in 2028-29, compared to 2025-26.Ensuring staff have the skills and training needed to work in social care is also essential, both to attract people to join and remain in the workforce, and for the provision of high-quality care and support. That is why we have developed the Care Workforce Pathway, the first national career framework for adult social care, and, we are investing £12 million in learning and development through the Learning and Development Support Scheme, to enable eligible staff to complete eligible courses and qualifications.These actions form part of our wider commitment to improving skills and support for the social care workforce.

What discussions he has had with private social care providers on levels of challenges for their staff.

I regularly hold discussions with providers from across the social care sector, including private and voluntary sectors, and with local authority providers. This includes roundtables and site visits.Department officials also regularly engage with private adult social care providers and sector representatives to understand the challenges faced by their workforce.In order to gain a full understanding of issues affecting the workforce, the Department commissioned ‘The Adult Social Care workforce and their work-related quality of life survey’ which provides detailed evidence on the issues most affecting staff.The full survey report is available at the following link:https://www.gov.uk/government/publications/adult-social-care-asc-workforce-and-work-related-quality-of-life

What steps he is taking to improve care for people with motor neurone disease.

NHS England commissions the specialised elements of motor neurone disease (MND) care that patients may receive from 27 specialised neurology centres across England. Within these specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals and specialised treatment and support, according to their needs. At the national level, there are a number of initiatives supporting service improvement and better care for patients with MND, including the Getting It Right First Time Programme for Neurology and the RightCare Progressive Neurological Conditions Toolkit. NHS England has also established a Neurology Transformation Programme, a multi-year, clinically-led programme, which has developed a new model of integrated care to support integrated care boards to deliver the right service, at the right time for all neurology patients, including those with MND. In August 2025, NHS England updated its service specification for specialised adult neurology services. The service specification outlines that specialised neurology centres must include services for neuromuscular disorders, including MND. Service specifications define the standards of care expected from organisations funded by NHS England to provide specialised care.

What steps his Department is taking to support research into motor neurone disease.

Government responsibility for delivering research into motor neurone disease (MND) is shared between the Department of Health and Social Care, with research delivered via the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation, and Technology, with research delivered via UK Research and Innovation (UKRI) and the Medical Research Council for MND.The Government is investing in MND research across a range of areas, including an £8 million investment via the NIHR into the EXPERTS-ALS. This is a pre-clinical study which is designed to accelerate the identification and testing of the most promising treatment candidates for treating amyotrophic lateral sclerosis (ALS): the most common form of MND.The MND Translational Accelerator, supported by £6 million of Government funding, is connecting the UK Dementia Research Institute, the UK MND Research Institute and Dementias Platform UK. Twelve projects have been funded through the Accelerator; all aimed at speeding up the development of treatments for MND.The NIHR and UKRI continue to welcome funding applications for research into MND.

What steps his Department is taking to help ensure that people who cannot afford anticancer treatment will continue to receive treatment beyond the stopping date of their anticancer agent being available on the NHS.

The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations.These are very difficult decisions to make, and it is right that they are taken independently and on the basis of the evidence. NICE’s methods and processes for making its recommendations are internationally respected and have been developed through extensive consultation. NICE is able to recommend the vast majority of new licensed medicines for use on the NHS, and many thousands of patients have benefited from access to medicines as a result.NICE’s guidance on the use of pembrolizumab for the treatment of untreated PD-L1-positive metastatic non-small-cell lung cancer recommends that treatment should be stopped at two years. This recommendation was based on the best available clinical evidence and was made in the interest of patient safety. During the development of guidance, NICE’s appraisal committee was informed by clinical experts that the optimal duration of treatment was unknown and, despite the medicine having low toxicity, long courses of intravenous infusion may be a burden to patients. Further information is set out in paragraph 3.6 of NICE’s published guidance at the following link:https://www.nice.org.uk/guidance/ta531/chapter/3-Committee-discussionThe Department and NHS England do not hold any data on the number of patients who are unable to self-fund treatment of medicines beyond any stopping rule set out in NICE’s guidance.

If he will make an assessment of the potential merits of making pembrolizumab available on the NHS for longer than two years.

The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations.These are very difficult decisions to make, and it is right that they are taken independently and on the basis of the evidence. NICE’s methods and processes for making its recommendations are internationally respected and have been developed through extensive consultation. NICE is able to recommend the vast majority of new licensed medicines for use on the NHS, and many thousands of patients have benefited from access to medicines as a result.NICE’s guidance on the use of pembrolizumab for the treatment of untreated PD-L1-positive metastatic non-small-cell lung cancer recommends that treatment should be stopped at two years. This recommendation was based on the best available clinical evidence and was made in the interest of patient safety. During the development of guidance, NICE’s appraisal committee was informed by clinical experts that the optimal duration of treatment was unknown and, despite the medicine having low toxicity, long courses of intravenous infusion may be a burden to patients. Further information is set out in paragraph 3.6 of NICE’s published guidance at the following link:https://www.nice.org.uk/guidance/ta531/chapter/3-Committee-discussionThe Department and NHS England do not hold any data on the number of patients who are unable to self-fund treatment of medicines beyond any stopping rule set out in NICE’s guidance.

If he will make an assessment of the adequacy of systems for determining the duration of NHS funding for anticancer agents.

The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations.These are very difficult decisions to make, and it is right that they are taken independently and on the basis of the evidence. NICE’s methods and processes for making its recommendations are internationally respected and have been developed through extensive consultation. NICE is able to recommend the vast majority of new licensed medicines for use on the NHS, and many thousands of patients have benefited from access to medicines as a result.NICE’s guidance on the use of pembrolizumab for the treatment of untreated PD-L1-positive metastatic non-small-cell lung cancer recommends that treatment should be stopped at two years. This recommendation was based on the best available clinical evidence and was made in the interest of patient safety. During the development of guidance, NICE’s appraisal committee was informed by clinical experts that the optimal duration of treatment was unknown and, despite the medicine having low toxicity, long courses of intravenous infusion may be a burden to patients. Further information is set out in paragraph 3.6 of NICE’s published guidance at the following link:https://www.nice.org.uk/guidance/ta531/chapter/3-Committee-discussionThe Department and NHS England do not hold any data on the number of patients who are unable to self-fund treatment of medicines beyond any stopping rule set out in NICE’s guidance.

Whether he is taking steps to ensure anticancer agents can be offered on the NHS for the duration of people’s cancer treatment.

The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations.These are very difficult decisions to make, and it is right that they are taken independently and on the basis of the evidence. NICE’s methods and processes for making its recommendations are internationally respected and have been developed through extensive consultation. NICE is able to recommend the vast majority of new licensed medicines for use on the NHS, and many thousands of patients have benefited from access to medicines as a result.NICE’s guidance on the use of pembrolizumab for the treatment of untreated PD-L1-positive metastatic non-small-cell lung cancer recommends that treatment should be stopped at two years. This recommendation was based on the best available clinical evidence and was made in the interest of patient safety. During the development of guidance, NICE’s appraisal committee was informed by clinical experts that the optimal duration of treatment was unknown and, despite the medicine having low toxicity, long courses of intravenous infusion may be a burden to patients. Further information is set out in paragraph 3.6 of NICE’s published guidance at the following link:https://www.nice.org.uk/guidance/ta531/chapter/3-Committee-discussionThe Department and NHS England do not hold any data on the number of patients who are unable to self-fund treatment of medicines beyond any stopping rule set out in NICE’s guidance.

What information his Department holds on the number of cancer patients who could not afford to continue using their anticancer agent beyond its NHS availability.

The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations.These are very difficult decisions to make, and it is right that they are taken independently and on the basis of the evidence. NICE’s methods and processes for making its recommendations are internationally respected and have been developed through extensive consultation. NICE is able to recommend the vast majority of new licensed medicines for use on the NHS, and many thousands of patients have benefited from access to medicines as a result.NICE’s guidance on the use of pembrolizumab for the treatment of untreated PD-L1-positive metastatic non-small-cell lung cancer recommends that treatment should be stopped at two years. This recommendation was based on the best available clinical evidence and was made in the interest of patient safety. During the development of guidance, NICE’s appraisal committee was informed by clinical experts that the optimal duration of treatment was unknown and, despite the medicine having low toxicity, long courses of intravenous infusion may be a burden to patients. Further information is set out in paragraph 3.6 of NICE’s published guidance at the following link:https://www.nice.org.uk/guidance/ta531/chapter/3-Committee-discussionThe Department and NHS England do not hold any data on the number of patients who are unable to self-fund treatment of medicines beyond any stopping rule set out in NICE’s guidance.

What data his Department holds on how many people resident outside the UK received medical treatment on the NHS in each of the last three years.

The Department does not collect or hold the information requested.

What data his Department holds on the cost to the public purse of treatment for people who came to Britain only for (a) health and (b) medical treatment in each of the last three years.

The Department does not collect or hold the information requested.

What steps his Department is taking to help ensure there is adequate mental health support in Ashfield constituency.

NHS Nottingham and Nottinghamshire Integrated Care Board is responsible for commissioning National Health Service mental health services to meet the needs of people in Ashfield.Nationally, the Government is committed to creating an environment that promotes good mental health, prevents people from developing mental health problems, and improves the lives of people living with a mental health problem including those in the Ashfield constituency.The 10-Year Health Plan sets out ambitious plans to transform mental health services to improve access and treatment, and to promote good mental health and wellbeing for the nation. This includes improving assertive outreach, investing in mental health emergency departments and neighbourhood mental health centres, and increasing access to talking therapies and evidence-based digital interventions.The recently published Medium Term Planning Framework sets targets for integrated care boards to expand coverage of mental health support teams in schools and colleges, expand NHS Talking Therapies and Individual Placement Support schemes, and eliminate inappropriate out-of-area placements by 2029.

What steps his Department is taking to help ensure veterans receive appropriate support for PTSD.

In addition to the mainstream mental health services commissioned by integrated care boards, NHS England commissions Op COURAGE which is the bespoke integrated veterans’ mental health and wellbeing service. The service provides a fully integrated mental health care pathway for veterans, which includes support for veterans with post-traumatic stress disorder. People benefit from personalised care plans, ensuring they can access support and treatment both in and out of hours. Op COURAGE is available across England and individuals can contact the service to make an appointment or ask someone to do this on their behalf.The Government recognises that not all veterans want to use veteran-specific mental health services and can instead choose to use mainstream services in the National Health Service, such as talking therapies, which are available to both veterans and civilians.

What steps he is taking to ensure that British Sign Language services are provided in care homes in England.

Local authorities are best placed to understand and plan for the needs of their population. That is why, under the Care Act 2014, local authorities are tasked with the duty to shape their care market and to commission a range of high-quality, sustainable, and person-centred care and support services to meet the diverse needs of all local people. This includes encouraging a wide range of service provision to ensure that people have a choice of appropriate services that put the wellbeing of the people who draw on care at the centre of decisions.Under the Equality Act 2010, health and social care organisations must make reasonable adjustments to ensure that disabled people are not disadvantaged. Since 2016, all National Health Service organisations and publicly funded social care providers are also expected to meet the Accessible Information Standard, which details the approach to supporting the information and communication support needs of people with a disability, impairment, or sensory loss.

What steps he is taking to help ensure that deaf people are not wrongly identified as lacking mental capacity due to communication barriers.

The Mental Capacity Act (MCA) 2005 already provides a legislative basis for providing interpreters, including British Sign Language interpreters, for people with specific communication needs. One of the foundational principles of the MCA is that individuals must be given all possible support to make, or participate in making, their own decisions. This includes taking "all practicable steps" to help them understand, weigh up information, and communicate their choice. Section 3.11 of the MCA Code of Practice provides detailed guidance on this.My Rt Hon. Friend, the Secretary of State for Health and Social Care will also launch a joint consultation with the Ministry of Justice on the Liberty Protection Safeguards in the first half of next year. This consultation will seek the views of those affected, including members of the deaf community and experts who work with deaf individuals. The responses from this consultation will be used to inform a final MCA Code of Practice which will be laid in Parliament.

What steps he is taking to help improve the (a) autonomy and (b) wellbeing of deaf residents in care homes.

Local authorities are best placed to understand and plan for the needs of their population. That is why, under the Care Act 2014, local authorities are tasked with the duty to shape their care market and to commission a range of high-quality, sustainable, and person-centred care and support services to meet the diverse needs of all local people. This includes encouraging a wide range of service provision to ensure that people have a choice of appropriate services that put the wellbeing of the people who draw on care at the centre of decisions.Under the Equality Act 2010, health and social care organisations must make reasonable adjustments to ensure that disabled people are not disadvantaged. Since 2016, all National Health Service organisations and publicly funded social care providers are also expected to meet the Accessible Information Standard, which details the approach to supporting the information and communication support needs of people with a disability, impairment, or sensory loss.

How many deaf individuals have been wrongly assessed under the Mental Capacity Act 2005 as a result of communication barriers in the last 12 months.

The Department does not hold the requested data.